Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Institute of Advanced Biosciences, INSERM 1209 CNRS 5309 University of Grenoble-Alpes, Grenoble, France.
BMC Cancer. 2020 Feb 10;20(1):110. doi: 10.1186/s12885-020-6599-8.
TP53 mutations occur in only about 3% of primary and 10-20% of relapse B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). However, alternative mechanisms may contribute to functionally impairing the p53 pathway in the absence of a mutation. Candidate mechanisms include overexpression of p53 mRNA variants encoding either dominant-negative p53 protein isoforms such as Delta40p53 and Delta133p53, or modulatory isoforms such as p53beta, which counteract the effects of Delta133p53 on replicative senescence in T-lymphocytes.
We used semi-quantitative reverse-transcriptase PCR (RT-PCR) and Western blot to investigate the expression of full length p53 (TAp53), Delta40p53, Delta133p53 or p53beta in diagnostic marrow from a clinical cohort of 50 BCP-ALL patients without TP53 mutation (29 males and 21 females, age range 2-14 years) and in the bone marrow cells of 4 healthy donors (used as controls).
Irrespective of isoforms, levels of p53 mRNA were low in controls but were increased by 2 to 20-fold in primary or relapse BCP-ALL. TAp53 was increased in primary BCP-ALL, Delta40p53 was elevated in relapse BCP-ALL, whereas Delta133p53 and p53beta were increased in both. Next, mRNA levels were used as a basis to infer the ratio between protein isoform levels. This inference suggested that, in primary BCP-ALL, p53 was predominantly in active oligomeric conformations dominated by TAp53. In contrast, p53 mostly existed in inactive quaternary conformations containing ≥2 Delta40 or Delta133p53 in relapse BCP-ALL. Western blot analysis of blasts from BCP-ALL showed a complex pattern of N-terminally truncated p53 isoforms, whereas TAp53beta was detected as a major isoform. The hypothesis that p53 is in an active form in primary B-ALL was consistent with elevated level of p53 target genes CDKN1A and MDM2 in primary cases, whereas in relapse BCP-ALL, only CDKN1A was increased as compared to controls.
Expression of p53 isoforms is deregulated in BCP-ALL in the absence of TP53 mutation, with increased expression of alternative isoforms in relapse BCP-ALL. Variations in isoform expression may contribute to functional deregulation of the p53 pathway in BCP-ALL, specifically contributing to its down-regulation in relapse forms.
TP53 突变仅发生于约 3%的初发和 10-20%的复发 B 细胞前体急性淋巴细胞白血病(BCP-ALL)患者中。然而,其他机制可能导致 p53 通路的功能障碍,而无需突变。候选机制包括 p53 mRNA 变体的过表达,这些变体编码显性负性 p53 蛋白异构体,如 Delta40p53 和 Delta133p53,或调节性异构体,如 p53beta,它们拮抗 Delta133p53 在 T 淋巴细胞复制性衰老中的作用。
我们使用半定量逆转录酶 PCR(RT-PCR)和 Western blot 检测了 50 例无 TP53 突变的 BCP-ALL 患者(男 29 例,女 21 例,年龄 2-14 岁)初发或复发时骨髓中的全长 p53(TAp53)、Delta40p53、Delta133p53 或 p53beta 的表达,并检测了 4 例健康供者(作为对照)的骨髓细胞中的表达。
无论异构体如何,对照组的 p53 mRNA 水平均较低,但在初发或复发 BCP-ALL 中增加 2 至 20 倍。TAp53 在初发 BCP-ALL 中增加,Delta40p53 在复发 BCP-ALL 中升高,而 Delta133p53 和 p53beta 在两者中均升高。接下来,根据 mRNA 水平推断蛋白异构体水平的比值。该推断表明,在初发 BCP-ALL 中,p53 主要以 TAp53 为主导的活性寡聚构象存在。相比之下,在复发 BCP-ALL 中,p53 主要以包含≥2 个 Delta40 或 Delta133p53 的无活性四聚体构象存在。BCP-ALL 原始细胞的 Western blot 分析显示 N 端截断的 p53 异构体存在复杂模式,而 TAp53beta 被检测为主要异构体。在初发 B-ALL 中 p53 处于活性形式的假设与初发病例中 p53 靶基因 CDKN1A 和 MDM2 的水平升高一致,而在复发 BCP-ALL 中,仅 CDKN1A 与对照组相比升高。
在无 TP53 突变的 BCP-ALL 中,p53 异构体的表达失调,在复发 BCP-ALL 中,替代异构体的表达增加。异构体表达的变化可能导致 BCP-ALL 中 p53 通路的功能失调,特别是在复发形式中下调。